Gold prices hit 2-week high as Trump-Fed feud escalates with Cook firing
Wednesday - Stifel analysts have revised the price target for OrthoPediatrics Corp. (NASDAQ:KIDS) to $32.00, down from the previous target of $40.00, while still holding a Buy rating on the company’s stock. The adjustment follows the company’s fourth-quarter earnings call for 2024, which was deemed more positive than anticipated, especially in light of their mid-January preannouncement and a somewhat cautious outlook on growth. According to InvestingPro data, analyst targets for the company currently range from $25 to $50, with two analysts recently revising their earnings expectations upward for the upcoming period.
During the earnings call, OrthoPediatrics’ management outlined several key sales drivers expected to propel the company forward in 2025. Among these drivers, the potential to expand the Specialty Bracing franchise was highlighted due to strong customer demand and a significant number of clinic expansions in the pipeline. The company’s strong growth trajectory is evidenced by its impressive 33.47% revenue growth in the last twelve months, according to InvestingPro data. Moreover, the company has experienced the strongest U.S. Trauma business in its history, supported by recent and ongoing set deployments, which may contribute to continued gains in market share. The company maintains a solid financial position with a current ratio of 7.17, indicating strong liquidity to support its expansion plans.
Additionally, management pointed to a series of product innovations that are slated for a broader rollout in 2025. These innovations include the PNP Tibia, 3P Hip, and DF2 Fracture Brace, which are anticipated to enhance the company’s surgical and non-surgical product offerings. The analyst, Rick Wise (LON:WISEa), expressed a positive outlook after the call, citing these factors as indicators of a promising year ahead for OrthoPediatrics.
Wise’s remarks following the earnings call underlined a sense of optimism for the company’s prospects in pediatric orthopedics. He anticipates that the company is well-positioned for further market share gains and a broadening product portfolio. Starting from the first quarter of 2025, he expects OrthoPediatrics to experience clear high-teens organic growth, setting a positive tone for the year.
In other recent news, OrthoPediatrics Corporation reported its fourth-quarter 2024 earnings, revealing a significant earnings per share (EPS) miss with a loss of -$0.69, compared to the forecasted -$0.30. However, the company’s revenue of $52.7 million exceeded expectations of $50.72 million, marking a 40% increase year-over-year. Despite the revenue beat, the company’s stock experienced a slight decline, reflecting investor concerns over the EPS miss. Analysts noted the company’s ambitious outlook for 2025, projecting revenue growth between 15% and 18%, supported by new product launches and market expansion. Additionally, OrthoPediatrics aims to achieve its first positive free cash flow by the fourth quarter of 2025. The company has been making strategic moves, including a $3.7 million restructuring charge due to office consolidation, which is expected to support its growth and profitability goals. The firm also emphasized its focus on expanding its international presence and product offerings, particularly in the pediatric orthopedic segment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.